Loading clinical trials...

A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITINGPHASE4

A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy

MEMENTO - A Phase 4, Single-arm, Open-label Clinical Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy to Assess the Impact on Myocardial Structure With Cardiac Magnetic Resonance Imaging (CMR)

NCT06112743•Bristol-Myers Squibb

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the mavacamten impact on myocardial structure with cardiac magnetic resonance imaging (CMR) in adult participants with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) \[New York Heart Association (NYHA) Functional Class II or III\].

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Diagnosed with obstructive hypertrophic cardiomyopathy (oHCM), in accordance with current American College of Cardiology Foundation/American Heart Association and European Society of Cardiology guidelines as below:.
•Left ventricular outflow tract (LVOT) peak gradient ≥ 30 mmHg and ≥ 50 mmHg after Valsalva or after exercise.
•Left ventricular ejection fraction (LVEF) ≥ 55% at rest.
•New York Heart Association (NYHA) functional class II or III symptoms.

Exclusion Criteria

•A known infiltrative or storage disorder causing cardiac hypertrophy that mimics oHCM.
•Documented obstructive coronary artery disease or history of myocardial infarction.
•A history of resuscitated sudden cardiac arrest or life-threatening ventricular arrhythmia within 6 months prior to screening.
•An implantable cardioverter defibrillator (ICD) or pacemaker, or another contraindication for cardiac magnetic resonance imaging (CMR).

Locations (23)

Local Institution - 0087

West Hollywood, California, United States

Local Institution - 0003

Atlanta, Georgia, United States

Local Institution - 0093

Boston, Massachusetts, United States

Local Institution - 0090

Cleveland, Ohio, United States

Local Institution - 0086

Pittsburgh, Pennsylvania, United States

Local Institution - 0017

Houston, Texas, United States

Local Institution - 0035

Murray, Utah, United States

Local Institution - 0076

Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina

Local Institution - 0075

Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina

Local Institution - 0079

Pilar, Buenos Aires, Argentina

Key Dates

Start Date

January 24, 2024

Primary Completion Date

July 9, 2026

Completion Date

July 9, 2026

Last Updated

September 22, 2025

Enrollment

ACTUAL participants

Conditions

Cardiomyopathy, Hypertrophic

Interventions

Mavacamten

DRUG

A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy

NCT06253221

Cardiomyopathy, Hypertrophic

View study

TERMINATEDPHASE1

A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CT-G20 in Subjects With Obstructive Hypertrophic Cardiomyopathy

NCT04418297

Cardiomyopathy, Hypertrophic Obstructive

View study

COMPLETEDNA

Pacemaker Therapy for Drug-refractory Symptoms in Mid-cavity Hypertrophic Cardiomyopathy

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 22, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Inclusion Criteria

Exclusion Criteria

A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy

A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CT-G20 in Subjects With Obstructive Hypertrophic Cardiomyopathy

Pacemaker Therapy for Drug-refractory Symptoms in Mid-cavity Hypertrophic Cardiomyopathy

Comparison of Squat-to-Stand Maneuver With Amyl Nitrite, Valsalva, and Exercise Stress Echocardiography in Inducing Latent Left Ventricular Outflow Obstruction in Hypertrophic Cardiomyopathy

A Phase 2 Open-label Pilot Study Evaluating MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction

Individualized Early Risk Assessment for Heart Diseases